AMEX:IBIO

Stock Analysis Report

Executive Summary

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally.

Risk Analysis

Earnings have declined by -23.97% per year over past 5 years

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 3 more risks


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has iBio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

30.6%

IBIO

-1.7%

US Biotechs

0.6%

US Market


1 Year Return

-63.7%

IBIO

12.6%

US Biotechs

24.6%

US Market

Return vs Industry: IBIO underperformed the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: IBIO underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

IBIOIndustryMarket
7 Day30.6%-1.7%0.6%
30 Day28.9%-1.9%3.0%
90 Day46.1%15.3%10.6%
1 Year-63.7%-63.7%13.6%12.6%27.3%24.6%
3 Year-92.3%-92.3%27.0%22.8%50.5%40.8%
5 Year-93.6%-93.6%4.6%-0.3%78.9%59.1%

Price Volatility Vs. Market

How volatile is iBio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is iBio undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether iBio is trading at an attractive price based on the cash flow it is expected to produce in the future. But as iBio has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is iBio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iBio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has iBio performed over the past 5 years?

-24.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IBIO is currently unprofitable.

Growing Profit Margin: IBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IBIO is unprofitable, and losses have increased over the past 5 years at a rate of -24% per year.

Accelerating Growth: Unable to compare IBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: IBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is iBio's financial position?


Financial Position Analysis

Short Term Liabilities: IBIO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: IBIO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: IBIO is debt free.

Reducing Debt: IBIO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: IBIO has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IBIO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBIO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IBIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.5% each year


Next Steps

Dividend

What is iBio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of iBio's salary, the management and board of directors tenure and is there insider trading?

6.2yrs

Average management tenure


CEO

Robert Kay (79yo)

11.4yrs

Tenure

US$347,604

Compensation

Mr. Robert B. Kay serves as Managing Director of Integrated BioPharma, Inc. He serves as a Principal, Co-Owner and Chairman of Seaway Biltmore, Inc., a hotel ownership and management company. Mr. Kay serve ...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD347.60K) is below average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.2yrs

Average Tenure

66yo

Average Age

Experienced Management: IBIO's management team is seasoned and experienced (6.2 years average tenure).


Board Age and Tenure

10.6yrs

Average Tenure

76yo

Average Age

Experienced Board: IBIO's board of directors are seasoned and experienced ( 10.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.6%.


Management Team

  • Robert Erwin (66yo)

    President

    • Tenure: 11.4yrs
    • Compensation: US$275.00k
  • Robert Kay (79yo)

    Executive Chairman & CEO

    • Tenure: 11.4yrs
    • Compensation: US$347.60k
  • Carlos Picosse

    Chief Executive Officer of IBio Brazil

    • Tenure: 6.2yrs
  • Renato Lobo

    Chief Medical Officer

    • Betsy Moyle

      Secretary

      • James Mullaney (48yo)

        Chief Financial Officer

        • Tenure: 2.8yrs
        • Compensation: US$319.17k
      • R. Holtz

        President of iBio CDMO

        • Tenure: 1yrs

      Board Members

      • Seymour Flug (84yo)

        Independent Director

        • Tenure: 7.1yrs
        • Compensation: US$51.87k
      • John McKey (76yo)

        Independent Director

        • Tenure: 11.4yrs
        • Compensation: US$51.87k
      • Glenn Chang (71yo)

        Independent Director

        • Tenure: 11.4yrs
        • Compensation: US$51.87k
      • Robert Kay (79yo)

        Executive Chairman & CEO

        • Tenure: 11.4yrs
        • Compensation: US$347.60k
      • Vidadi Yusibov (58yo)

        Member of Scientific Advisory Board

        • Tenure: 15.3yrs
      • James Hill (73yo)

        Independent Director

        • Tenure: 11.4yrs
        • Compensation: US$76.87k
      • Philip Russell (87yo)

        Independent Director

        • Tenure: 9.8yrs
        • Compensation: US$51.87k
      • Timothy Blackwell

        Member of Clinical Advisory Board

        • Tenure: 5.5yrs
      • Richard Silver

        Member of Clinical Advisory Board

        • Tenure: 5.5yrs
      • J. Huggins

        Member of Clinical Advisory Board

        • Tenure: 5.5yrs

      Company Information

      iBio, Inc.'s company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: iBio, Inc.
      • Ticker: IBIO
      • Exchange: AMEX
      • Founded:
      • Industry: Biotechnology
      • Sector: Pharmaceuticals & Biotech
      • Market Cap: US$18.202m
      • Shares outstanding: 59.33m
      • Website: https://www.ibioinc.com

      Number of Employees


      Location

      • iBio, Inc.
      • 600 Madison Avenue
      • Suite 1601
      • New York
      • New York
      • 10022
      • United States

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      IBIOAMEX (NYSE MKT LLC)YesCommon StockUSUSDAug 2008
      0JVNDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2008

      Biography

      iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company’s services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2020/01/24 00:41
      End of Day Share Price2020/01/23 00:00
      Earnings2019/09/30
      Annual Earnings2019/06/30


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.